See more : Tonopah Divide Mining Co. (TODM) Income Statement Analysis – Financial Results
Complete financial analysis of Ipsen S.A. (IPSEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ipsen S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ulta Beauty, Inc. (ULTA) Income Statement Analysis – Financial Results
- Summit Midstream Partners, LP (SMLP) Income Statement Analysis – Financial Results
- Marfrig Global Foods S.A. (MRFG3.SA) Income Statement Analysis – Financial Results
- Julius Bär Gruppe AG (0QO6.L) Income Statement Analysis – Financial Results
- The Joint Corp. (JYNT) Income Statement Analysis – Financial Results
Ipsen S.A. (IPSEF)
About Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31B | 3.16B | 3.00B | 2.69B | 2.69B | 2.35B | 2.01B | 1.67B | 1.52B | 1.33B | 1.28B | 1.28B | 1.23B | 1.17B | 1.11B | 1.04B | 993.76M | 861.68M | 788.71M | 723.99M |
| Cost of Revenue | 571.20M | 527.70M | 538.00M | 490.60M | 488.00M | 454.20M | 385.60M | 353.30M | 336.80M | 310.00M | 253.39M | 254.77M | 249.24M | 236.19M | 237.81M | 219.93M | 199.03M | 181.38M | 176.83M | 176.31M |
| Gross Profit | 2.74B | 2.63B | 2.46B | 2.20B | 2.20B | 1.89B | 1.63B | 1.32B | 1.18B | 1.02B | 1.03B | 1.02B | 985.67M | 934.11M | 874.58M | 818.18M | 794.73M | 680.30M | 611.88M | 547.68M |
| Gross Profit Ratio | 82.72% | 83.28% | 82.06% | 81.74% | 81.88% | 80.66% | 80.83% | 78.86% | 77.85% | 76.73% | 80.23% | 80.06% | 79.82% | 79.82% | 78.62% | 78.81% | 79.97% | 78.95% | 77.58% | 75.65% |
| Research & Development | 619.30M | 445.30M | 428.40M | 405.60M | 388.80M | 302.10M | 265.80M | 208.90M | 192.60M | 186.90M | 259.05M | 248.55M | 253.59M | 221.13M | 197.29M | 182.92M | 184.74M | 178.35M | 167.57M | 140.79M |
| General & Administrative | 217.80M | 205.80M | 199.60M | 187.80M | 181.40M | 165.70M | 140.80M | 129.40M | 122.90M | 111.20M | 103.82M | 99.09M | 101.47M | 98.25M | 88.46M | 85.90M | 80.43M | -232.58M | -225.80M | -318.06M |
| Selling & Marketing | 917.10M | 833.40M | 835.70M | 784.00M | 838.60M | 787.40M | 715.90M | 608.40M | 541.40M | 464.10M | 451.27M | 473.48M | 425.15M | 422.81M | 396.14M | 358.40M | 321.05M | 307.80M | 292.59M | 319.24M |
| SG&A | 1.13B | 1.04B | 1.04B | 971.80M | 1.02B | 953.10M | 856.70M | 737.80M | 664.30M | 575.30M | 555.09M | 572.57M | 526.62M | 521.06M | 484.61M | 444.30M | 401.48M | 75.22M | 66.79M | 1.18M |
| Other Expenses | 165.00M | 17.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -21.70M | -7.20M | -9.20M | -6.26M | -20.21M | 0.00 | 12.76M | -3.47M | -677.00K | 17.41M | -12.62M | -2.62M | -1.58M |
| Operating Expenses | 1.92B | 1.76B | 1.58B | 1.48B | 1.54B | 1.34B | 1.22B | 968.40M | 868.20M | 771.10M | 824.79M | 847.08M | 788.13M | 705.15M | 702.11M | 635.48M | 585.85M | 485.82M | 450.71M | 411.01M |
| Cost & Expenses | 2.49B | 2.29B | 2.12B | 1.97B | 2.03B | 1.79B | 1.61B | 1.32B | 1.21B | 1.08B | 1.08B | 1.10B | 1.04B | 941.35M | 939.91M | 855.41M | 784.88M | 667.19M | 627.55M | 587.32M |
| Interest Income | 18.30M | 500.00K | 2.90M | 2.30M | 2.60M | 3.90M | 1.10M | 1.20M | 1.10M | 1.40M | 1.35M | 1.67M | 1.75M | 2.24M | 2.70M | 21.43M | 11.54M | 7.97M | -1.38M | 0.00 |
| Interest Expense | 37.70M | 18.50M | 23.70M | 27.50M | 31.40M | 10.20M | 11.20M | 7.00M | 3.90M | 5.90M | 4.82M | 5.37M | 1.76M | 1.59M | 4.40M | 4.35M | 13.49M | 2.48M | 6.53M | 0.00 |
| Depreciation & Amortization | 87.90M | 201.30M | 246.40M | 234.70M | 161.20M | 142.60M | 97.90M | 49.10M | 43.70M | 50.20M | 25.75M | 72.56M | 114.69M | 39.39M | 44.94M | 50.65M | 41.23M | 49.94M | 28.87M | 35.02M |
| EBITDA | 887.10M | 1.07B | 1.06B | 794.60M | 153.30M | 646.80M | 487.70M | 343.90M | 284.90M | 262.40M | 232.00M | 198.19M | 148.00M | 166.37M | 216.64M | 246.78M | 258.80M | 237.76M | 190.41M | 161.42M |
| EBITDA Ratio | 26.83% | 38.09% | 36.99% | 35.51% | 31.65% | 29.12% | 24.44% | 23.33% | 23.57% | 22.02% | 17.76% | 19.30% | 22.64% | 22.77% | 19.48% | 23.00% | 26.32% | 28.79% | 24.07% | 22.30% |
| Operating Income | 816.00M | 729.90M | 849.50M | 521.00M | -33.40M | 519.40M | 397.20M | 304.70M | 244.00M | 221.40M | 190.75M | 114.80M | 75.78M | 128.80M | 172.47M | 180.09M | 208.89M | 187.22M | 161.69M | 125.92M |
| Operating Income Ratio | 24.68% | 23.12% | 28.33% | 19.40% | -1.24% | 22.12% | 19.74% | 18.23% | 16.05% | 16.62% | 14.88% | 8.99% | 6.14% | 11.01% | 15.50% | 17.35% | 21.02% | 21.73% | 20.50% | 17.39% |
| Total Other Income/Expenses | -54.50M | -23.80M | -35.50M | 6.30M | -5.30M | -25.40M | -26.50M | -6.90M | -6.70M | -15.10M | 10.75M | 5.45M | -3.94M | -3.41M | -5.16M | 1.07M | -2.03M | -1.54M | -6.68M | -10.28M |
| Income Before Tax | 761.50M | 706.10M | 814.40M | 528.60M | -38.70M | 494.00M | 370.70M | 297.80M | 237.30M | 206.30M | 181.77M | 120.26M | 41.37M | 125.40M | 167.31M | 181.16M | 206.86M | 185.68M | 155.01M | 115.64M |
| Income Before Tax Ratio | 23.03% | 22.37% | 27.15% | 19.68% | -1.44% | 21.04% | 18.43% | 17.82% | 15.61% | 15.48% | 14.18% | 9.41% | 3.35% | 10.71% | 15.04% | 17.45% | 20.82% | 21.55% | 19.65% | 15.97% |
| Income Tax Expense | 136.20M | 112.30M | 168.20M | -17.80M | 19.60M | 108.10M | 101.40M | 73.50M | 49.80M | 53.80M | 39.56M | 24.44M | -13.34M | 16.96M | 10.59M | 33.32M | 54.48M | 40.89M | 32.64M | 40.24M |
| Net Income | 644.40M | 648.60M | 646.60M | 548.00M | -50.70M | 389.50M | 272.30M | 225.90M | 189.90M | 153.50M | 152.50M | -29.49M | 424.00K | 95.27M | 156.58M | 146.56M | 150.61M | 144.01M | 119.23M | 83.00M |
| Net Income Ratio | 19.49% | 20.55% | 21.56% | 20.40% | -1.88% | 16.59% | 13.54% | 13.52% | 12.49% | 11.52% | 11.90% | -2.31% | 0.03% | 8.14% | 14.08% | 14.12% | 15.16% | 16.71% | 15.12% | 11.46% |
| EPS | 7.09 | 7.87 | 7.82 | 6.61 | -0.61 | 4.70 | 3.30 | 2.74 | 2.31 | 1.87 | 1.84 | -0.35 | 0.01 | 1.13 | 1.86 | 1.75 | 1.80 | 1.71 | 1.42 | 0.99 |
| EPS Diluted | 7.40 | 7.81 | 7.76 | 6.57 | -0.61 | 4.68 | 3.28 | 2.73 | 2.30 | 1.87 | 1.83 | -0.35 | 0.01 | 1.13 | 1.86 | 1.74 | 1.79 | 1.71 | 1.42 | 0.99 |
| Weighted Avg Shares Out | 87.08M | 82.41M | 82.65M | 82.96M | 83.10M | 82.90M | 82.55M | 82.31M | 82.27M | 82.09M | 83.03M | 83.16M | 83.22M | 84.51M | 84.30M | 83.93M | 83.88M | 84.21M | 84.02M | 84.02M |
| Weighted Avg Shares Out (Dil) | 83.38M | 83.10M | 83.36M | 83.45M | 83.10M | 83.25M | 83.03M | 82.62M | 82.70M | 82.22M | 83.16M | 83.46M | 83.47M | 84.51M | 84.30M | 84.02M | 83.97M | 84.21M | 84.02M | 84.02M |
Source: https://incomestatements.info
Category: Stock Reports